Phase I/II clinical trials with Ivosidenib (targeting IDH1-R132) and Evasidenib (targeting IDH2R140Q) in refractory or relapsed adult AML patients show overall response rates >40% with about 20% complete remission over several months underlining the potential for these compounds for personalized therapeutic strategies (152, 153). The gene discussed is IDH1; the disease is acute myeloid leukemia.